Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

tippy_09137 4 posts  |  Last Activity: May 26, 2015 7:20 PM Member since: Dec 9, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • 4 Sullivan, eugene jeffrey May 26, 2015
    4 Schaeffer, orlov s nicole May 26, 2015
    4 Pellizzari, christine a May 26, 2015
    4 Lewis, william May 26, 2015
    4 Drechsler, andrew t May 26, 2015

  • Reply to

    OT: ISR stock

    by tippy_09137 May 20, 2015 10:29 PM
    tippy_09137 tippy_09137 May 20, 2015 10:31 PM Flag

    Why doesn't INSM release news on the results from the poster board? Better than expected!!

  • tippy_09137 by tippy_09137 May 20, 2015 10:29 PM Flag

    IsoRay reports that the survival rate at 5 years was 100% for Cesium-131 lung cancer treatment group, which included many high risk patients, and Cesium-131 added no noticeable side effects (ISR) :

    The study noted that the survival rate at 5 years was exceptional for the Cesium-131 group, which included many high risk patients, and Cesium-131 added no noticeable side effects. Treatment with Cesium-131 was performed at the time of the surgery as a single treatment, in contrast to another treatment option, external radiation, which requires numerous hospital visit.

  • tippy_09137 by tippy_09137 Mar 8, 2015 8:24 AM Flag

    Anyone following this stock? Looks like has great growth potential.

    "We are extremely pleased with the growth of Forfivo XL(R) throughout 2014 and we believe that this growth will continue, especially as Edgemont increased its salesforce threefold in mid-December, 2014" stated Dr. Horst G. Zerbe, President and CEO of IntelGenx. "The marketing and sales efforts that our partner, Edgemont Pharmaceuticals, has invested in the commercialization of Forfivo XL(R) have ensured that a more convenient and safe alternative for patients requiring high-dose anti-depressant therapy is widely available in the US. Forfivo XL(R) generated in excess of $1.1 million (unaudited) of revenue for IntelGenx in 2014 and we anticipate significantly higher revenue from the product in 2015."

INSM
27.10+0.36(+1.35%)Jul 31 4:00 PMEDT